The collaboration will leverage PathAI's artificial intelligence (AI) tools that are used to evaluate liver pathology and Summit's expertise in NASH drug development and accelerated study execution.

PathAI and Summit Clinical Research will provide sponsors with an offering that features trial design; site activation and patient enrollment; and wet lab, diagnostic, and AI-pathology deployment services, the companies said.

The companies announced that they have contracted with a sponsor to provide pathology services for a phase II clinical trial, with several additional trials that are currently under negotiation.